Questions Register · KLOW Peptide
Frequently asked questions about KLOW peptide — indexed and answered from the literature
Direct answers to the most common questions about the KLOW blend, its components, and the state of the evidence.
What is KLOW peptide?
KLOW peptide is a co-formulated research blend of four distinct peptides: KPV (Lys-Pro-Val, an anti-inflammatory tripeptide), GHK-Cu (Glycyl-L-Histidyl-L-Lysine Copper(II) complex, studied for collagen and matrix synthesis), BPC-157 (a 15-amino-acid peptide with an extensive rodent tissue-repair literature), and TB-500 (a heptapeptide fragment of thymosin beta-4, linked to cell migration and wound closure). The canonical research vial contains 80 mg total, with GHK-Cu as the dominant component at 50 mg.
What is KLOW peptide used for?
In research contexts, the individual components have been studied for tissue repair, tendon and muscle healing, anti-inflammatory effects, and skin collagen synthesis. In rat wound models, thymosin beta-4 (the protein from which TB-500's LKKTET fragment is derived) increased re-epithelialization by 42% at day 4 and 61% at day 7 [1]. The four-peptide KLOW blend itself has not been tested in any controlled study for any specific use.
Does KLOW peptide work?
The individual components have each produced measurable results in their respective study models. TB-500/thymosin beta-4 showed significant wound-healing improvements in rat models [1]; BPC-157 accelerated transected-Achilles healing and muscle repair in rodents [2]; KPV reduced colitis in mouse models [3]; GHK-Cu improved collagen production in clinical skin studies [4]. Whether the four-component blend works as a combination is unknown — no controlled blend study exists.
How long does it take for KLOW peptide to work?
No controlled KLOW-blend study has measured a timeline for the combination. In the individual component literature, thymosin beta-4 produced measurable wound-healing differences at 4 and 7 days in rat models [1]. BPC-157's biomechanical improvements in transected-Achilles studies were measured over several weeks [2]. These component timelines cannot be applied to the blend without combination study data.
How long does it take to see results from KLOW peptide?
Research-use community reports describe observable changes — particularly for tendon and joint recovery — over approximately three to four weeks, but these are anecdotal accounts from uncontrolled, unverified conditions. The controlled animal data for BPC-157's Achilles healing was measured over a multi-week recovery period [2]. No blend-level timeline has been established in any study.
What are the benefits of the KLOW peptide blend?
The component literature documents: +42%/+61% re-epithelialization in rat wound models for TB-500/thymosin beta-4 [1]; accelerated tendon and muscle repair for BPC-157 [2]; NF-kappaB suppression and reduced colitis severity for KPV [3]; and collagen synthesis and transcriptomic modulation for GHK-Cu [4][5]. These are component-level findings. No study has demonstrated these benefits for the four-peptide combination. Community reports of benefit are anecdotal and not clinical evidence.
How does KLOW compare to the Wolverine blend?
KLOW and WOLVERINE are distinct research blends with different constituent selections and ratios. This site covers KLOW only and does not have access to a signed Wolverine corpus to make specific comparisons. KLOW contains KPV, GHK-Cu, BPC-157, and TB-500; the constituent overlap and ratio differences between KLOW and WOLVERINE would need to be evaluated against each blend's own published component literature.
Has anyone combined BPC-157, TB-500, and GHK-Cu together?
No peer-reviewed controlled study has tested BPC-157, TB-500, and GHK-Cu in combination — either as a trio or as the four-peptide KLOW blend that adds KPV. The combination is a research-chemical compounding convention, not a tested formulation. Community anecdotes exist but are not evidence. The combination-study column in the KLOW record is blank.
Where do you inject KLOW peptide?
Component-level research has used subcutaneous and intraperitoneal injection in rodent studies; BPC-157 has also been studied via local injection near injury sites and intra-articularly. KPV has been delivered orally (in drinking water) in mouse models, with uptake via the intestinal PepT1 transporter [3]. This site documents research routes — it does not provide injection instructions. No validated human administration protocol exists for the KLOW blend.
How much KLOW peptide per day?
No validated human daily dose exists for the KLOW blend or for any of its four components in this combination. The canonical research vial contains 80 mg total (GHK-Cu 50 + BPC-157 10 + TB-500 10 + KPV 10 mg). Component animal-study doses range from picogram to microgram quantities and cannot be converted to human equivalents without clinical-pharmacokinetic data that do not exist.
Is KLOW peptide safe?
No controlled safety study has evaluated the four-peptide KLOW combination. For BPC-157 alone, a 2025 IV safety pilot in two healthy adults found no adverse events at 10-20 mg [6] — a two-subject, non-efficacy report. A 2026 Sports Medicine review noted that unapproved peptides including TB-500 and BPC-157 have scarce human safety data and potential for serious harm [7]. The WADA prohibition on TB-500 is a separate regulatory-safety fact.
How do you reconstitute KLOW peptide?
Lyophilized research peptide blends are typically reconstituted with bacteriostatic water for laboratory handling purposes. Copper(II) in GHK-Cu can participate in redox chemistry — a theoretical consideration when co-dissolving with the other three peptides. This site does not provide preparation instructions; reconstitution conditions for the specific four-peptide blend have not been formally characterized in the literature.
Does KLOW peptide help with weight loss?
No. None of the four components in KLOW — KPV, GHK-Cu, BPC-157, or TB-500 — is a GLP-1 receptor agonist, an incretin-pathway agent, or an otherwise established weight-loss compound. KLOW is a tissue-repair and anti-inflammatory research blend, not a metabolic or weight-management compound. Any framing of KLOW as a weight-loss peptide is unsupported by the component literature.
How often should you take KLOW peptide?
No validated frequency exists for the KLOW blend. Component animal studies used once-daily intraperitoneal dosing for BPC-157 in Achilles tendon models [2] and continuous oral administration (in drinking water) for KPV in colitis models [3]. These study frequencies are not translatable to human dosing schedules without clinical data. This site documents the research; it does not prescribe use.
Why is KLOW peptide blue?
GHK-Cu carries a chelated copper(II) ion — the same class of copper complex responsible for the blue-green color in copper-containing compounds like copper sulfate. With GHK-Cu constituting approximately 62.5% of the canonical vial (50 of 80 mg), the lyophilized blend or its reconstituted solution takes on a characteristic blue-green tint from the copper complex. This is a property of the GHK-Cu component, not of the blend as a whole.
How many mg of KLOW peptide per day?
No clinically validated mg/day figure exists for the KLOW blend. The canonical research vial is 80 mg total per vial. KPV's PepT1 transporter Km is approximately 160 micromolar in intestinal epithelial cells [3]; BPC-157 animal doses ranged from 10 picograms to 10 micrograms per rat in tendon studies [2]. These figures are research reference points, not human dosing guidance.
What are the side effects of the KLOW peptide?
For BPC-157, the 2025 IV safety pilot in two adults recorded no adverse events at up to 20 mg IV [6]. Community reports (anecdotal, not clinical evidence) include injection-site redness and swelling, initial fatigue, mild headache, flushing, and occasional transient nausea. Safety cautions grounded in mechanism include the WADA prohibition (TB-500 arm), pro-angiogenic risk in active cancer (BPC-157, TB-500, GHK-Cu arms), and copper-load concern for copper-handling disorders (GHK-Cu arm). See the KLOW effects page for the full safety record.
What does the KLOW peptide do?
Each component targets a different node of the tissue-repair signaling network: KPV suppresses NF-kappaB and MAPK inflammatory pathways in epithelial cells [3]; GHK-Cu drives extracellular-matrix gene expression and supplies copper for collagen crosslinking [4][5]; BPC-157 activates the VEGFR2/PI3K/Akt/eNOS angiogenic cascade and upregulates tendon growth-hormone receptors [2]; TB-500/thymosin beta-4 sequesters G-actin to promote cell migration and re-epithelialization [1][12]. What the combination does has not been established.
What is the KLOW peptide dosage?
The canonical research vial dose is 80 mg total — GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg, KPV 10 mg. This is a research-compounding convention, not a clinically validated formulation. No FDA-reviewed dose range, pharmacokinetic characterization, or approved labeling exists for KLOW peptide. Component-level research doses are documented on the dosage page and are not translatable into KLOW blend recommendations.
What is the KLOW peptide dosage and frequency?
No validated dosage and frequency exists for the KLOW blend. A pharmacokinetic mismatch is inherent: the tripeptides KPV and GHK-Cu clear faster than BPC-157, which itself has a short half-life in rat studies, and TB-500 behaves differently from full-length thymosin beta-4. A single co-formulated dose cannot maintain all four components at matched exposures, and no combination-dose modeling exists. See the dosage research page for the full context.
What is in the 80mg KLOW peptide vial?
The canonical 80 mg KLOW research vial contains: GHK-Cu 50 mg (approximately 62.5% by mass, MW 402.92 Da, CAS 89030-95-5), BPC-157 10 mg (MW 1419.53 Da, CAS 137525-51-0), TB-500 10 mg (MW 889.02 Da, Ac-LKKTETQ fragment), and KPV 10 mg (MW 342.44 Da, CAS 67727-97-3). The four components remain separate molecules in the reconstituted solution — no new chemical entity is formed.
What are KLOW peptide benefits and side effects?
Benefits are component-attributed: TB-500/thymosin beta-4 showed +42-61% wound re-epithelialization in rats [1]; BPC-157 accelerated Achilles tendon and muscle healing in rodents [2]; KPV reduced gut inflammation in mouse models [3]; GHK-Cu improved skin collagen in clinical studies [4]. Community-reported benefits include tendon/joint recovery and reduced inflammation — anecdotal, not clinical evidence. Side effects catalogued in the KLOW effects record include the WADA prohibition (TB-500), pro-angiogenic concerns, and injection-site reactions from community reports.